Successful Treatment of Complex and Refractory Rosacea Using Platelet-Rich Plasma Injection Therapy: Case Series and Review of the Literature.

[BACKGROUND] Rosacea is a chronic inflammatory skin disease that affects a notable proportion of the adult population. Platelet-rich plasma (PRP) has been widely used to treat various inflammatory diseases due to its potent anti-inflammatory and antibacterial properties. Considering its therapeutic potential, PRP is emerging as a promising option for managing rosacea.

[AIMS] To evaluate the efficacy and safety of PRP therapy in treating distinct clinical presentations of rosacea and explore its potential as an alternative to systemic treatments, particularly in cases where conventional therapies are contraindicated.

[METHODS] Five patients of rosacea with distinct presentations were treated with PRP therapy. The treatment outcomes were analyzed, and a brief review of relevant literature was conducted to contextualize the findings. Clinical efficacy was assessed using clinical photographs captured at 0 and 30 days after baseline according to the National Rosacea Society Standard (NRSS) grading system. Additionally, the efficacy of combining PRP injections with delicate pulsed light therapy or botulinum toxin injections was assessed.

[RESULTS] PRP therapy demonstrated significant efficacy and safety in treating rosacea, offering a viable alternative to systemic treatments. The combination of PRP with delicate pulsed light therapy or botulinum toxin injections showed enhanced therapeutic outcomes, not only alleviating rosacea symptoms but also reducing or eliminating patients' dependence on oral medications.

[CONCLUSIONS] PRP therapy, both as a standalone treatment and in combination with other modalities, represents a promising approach for managing rosacea. These findings highlight the potential of PRP to address the limitations of conventional therapies and improve patient outcomes. Further research is warranted to validate these results and optimize treatment protocols.